Literature DB >> 11739068

Continuation treatment of delusional depression in older adults.

B S Meyers1, S A Klimstra, M Gabriele, M Hamilton, T Kakuma, F Tirumalasetti, G S Alexopoulos.   

Abstract

Delusional depression responds poorly to acute antidepressant monotherapy but appears to respond to intensive combination pharmacotherapy, however with poor short-term outcomes after initial improvement, particularly in later life. The authors compared the efficacy and safety of continuation combination therapy to monotherapy among older patients after remission from a delusional depression. Twenty-nine older adults with SCID-diagnosed major depression with delusions received continuation treatment with nortriptyline-plus-perphenazine or nortriptyline-plus-placebo under randomized double-blind conditions after achieving remission after ECT. Of the 28 subjects included in efficacy analyses, 25% suffered relapses. The relapse frequency was nonsignificantly greater in combination therapy than in monotherapy subjects. However, combination subjects had significantly more extrapyramidal symptoms, an increased incidence of tardive dyskinesia, and a greater number of falls. Continuation treatment with a conventional antipsychotic does not decrease relapse rates but is associated with significant untoward adverse events in older persons after recovery from a delusional depression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739068

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  9 in total

Review 1.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).

Authors:  Charles H Kellner; Rebecca G Knapp; Georgios Petrides; Teresa A Rummans; Mustafa M Husain; Keith Rasmussen; Martina Mueller; Hilary J Bernstein; Kevin O'Connor; Glenn Smith; Melanie Biggs; Samuel H Bailine; Chitra Malur; Eunsil Yim; Shawn McClintock; Shirlene Sampson; Max Fink
Journal:  Arch Gen Psychiatry       Date:  2006-12

Review 3.  Late-life psychosis: diagnosis and treatment.

Authors:  Michael M Reinhardt; Carl I Cohen
Journal:  Curr Psychiatry Rep       Date:  2015-02       Impact factor: 5.285

Review 4.  Co-occurring depressive symptoms in the older patient with schizophrenia.

Authors:  John W Kasckow; Sidney Zisook
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 5.  Challenges in the treatment of major depressive disorder with psychotic features.

Authors:  Anthony J Rothschild
Journal:  Schizophr Bull       Date:  2013-04-18       Impact factor: 9.306

6.  A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).

Authors:  Barnett S Meyers; Alastair J Flint; Anthony J Rothschild; Benoit H Mulsant; Ellen M Whyte; Catherine Peasley-Miklus; Eros Papademetriou; Andrew C Leon; Moonseong Heo
Journal:  Arch Gen Psychiatry       Date:  2009-08

7.  Influence of adjuvant nortriptyline on the efficacy of electroconvulsive therapy: A randomized controlled trial and 1-year follow-up.

Authors:  Esther M Pluijms; Astrid M Kamperman; Witte J G Hoogendijk; Walter W van den Broek; Tom K Birkenhäger
Journal:  Acta Psychiatr Scand       Date:  2022-02-18       Impact factor: 7.734

8.  Clinical classification in mental health at the cross-roads: which direction next?

Authors:  Ian B Hickie; Jan Scott; Daniel F Hermens; Elizabeth M Scott; Sharon L Naismith; Adam J Guastella; Nick Glozier; Patrick D McGorry
Journal:  BMC Med       Date:  2013-05-14       Impact factor: 8.775

9.  Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.

Authors:  Alastair J Flint; Barnett S Meyers; Anthony J Rothschild; Ellen M Whyte; Benoit H Mulsant; Matthew V Rudorfer; Patricia Marino
Journal:  BMC Psychiatry       Date:  2013-01-25       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.